Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Trading Down 6.6% – What’s Next?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM)’s stock price was down 6.6% during mid-day trading on Monday . The stock traded as low as C$0.29 and last traded at C$0.29. Approximately 4,800 shares traded hands during mid-day trading, an increase of 68% from the average daily volume of 2,858 shares. The stock had previously closed at C$0.31.

Zomedica Pharmaceuticals Corp. (ZOM.V) Stock Performance

The company has a debt-to-equity ratio of 4.91, a current ratio of 15.31 and a quick ratio of 15.25. The stock has a 50-day moving average price of C$0.29 and a 200-day moving average price of C$0.28. The company has a market capitalization of C$36.73 million and a price-to-earnings ratio of -2.61.

Zomedica Pharmaceuticals Corp. (ZOM.V) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination.